Johnson & Johnson's Rybrevant Approved for EGFR-Mutated NSCLC, Reduces Progression Risk by 50%

Sep 20, 2024, 09:56 AM

Rybrevant (amivantamab-vmjw), developed by Johnson & Johnson, has received FDA approval in the U.S. for the treatment of second-line EGFR-mutated advanced lung cancer (NSCLC). This approval marks the third new indication for Johnson & Johnson in 2024. Rybrevant, in combination with standard of care, is the first and only targeted regimen to reduce the risk of disease progression by more than 50% in patients with EGFR ex19del/L858R substitution mutations after progression on or after EGFR TKI (MARIPOSA-2). Johnson & Johnson aims to achieve $5 billion in sales for Rybrevant.